Market Cap 476.07M
Revenue (ttm) 84.61M
Net Income (ttm) -81.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -96.06%
Debt to Equity Ratio 0.00
Volume 676,800
Avg Vol 1,234,156
Day's Range N/A - N/A
Shares Out 88.33M
Stochastic %K 10%
Beta 1.86
Analysts Strong Sell
Price Target $7.50

Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor an...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 752 1300
Fax: 650 752 1301
Address:
6600 Dumbarton Circle, Fremont, United States
Bulltrader988
Bulltrader988 Aug. 4 at 6:26 PM
$PSNL tomorrow after market 👃👀
0 · Reply
Bulltrader988
Bulltrader988 Aug. 3 at 7:51 PM
$PSNL 👃👀 https://www.nationalgeographic.com/health/article/cancer-recurrence-tumor-dna-blood-test
0 · Reply
Bulltrader988
Bulltrader988 Aug. 2 at 12:31 PM
$PSNL earnings tuesday after market 👃👀
0 · Reply
Wax_Bean_futures
Wax_Bean_futures Aug. 1 at 3:51 PM
$PSNL About to turn green. Rate Cuts on the horizon. Loading more!
0 · Reply
Farorm
Farorm Aug. 1 at 1:12 PM
$PSNL more red to come, yay
1 · Reply
BeeDecay
BeeDecay Aug. 1 at 11:50 AM
$PSNL Some views and opinions. 1. SAGA was fast to get reimbursement. Faster than we hoped for, and for a test with noninferior capabilities in breast cancer. That's a bummer. 2. Personalis has pushed its NeXT Dx through the Medicare reimbursement path back in early 2024, so they know how to do things. Trust the (slow) process. 3. Recall that SAGA's Pathlight uses few SVs whereas we use 1,800 SNVs. In layman's terms: SAGA uses ultra sensitive larger DNA parts specific for a certain tumor type. We use 1,800 SNVs (so looking into single nucleotides, the smallest building blocks of the DNA) that are believed to cover many tumor types. 4. Due to point 3 Personalis should have far less work expanding towards other tumor types, whereas SAGA needs to define the specific SVs for each new indication they want to target. 5. The SAGA and $PSNL approach are more sensitive than the $NTRA approach which is simpler yet generic. Natera used it to be first mover in the MRD space. With success.
0 · Reply
Farorm
Farorm Jul. 31 at 1:46 PM
$PSNL -20% in a week, yay.
1 · Reply
arribaStocktrading
arribaStocktrading Jul. 31 at 12:31 PM
$PSNL Are we all having conversations with AI? So SAGA is a Swedish firm and they have a US presence in Morrisville, NC. They have about 40 employees and were only expected to generate $7 million in Annual Revenues this year. What I was most curious about is how long it took them to gain Medicare reimbursement approval: "SAGA Diagnostics received Medicare coverage for its Pathlight™ MRD test on July 30, 2025, following a rigorous review by Palmetto GBA’s MolDX program. The approval was based primarily on data from the TRACER study, which was published in Clinical Cancer Research in January 2025. That means it took roughly 6 to 7 months from the time their pivotal clinical data was published to the final coverage determination — a relatively swift timeline in the world of molecular diagnostics. "
1 · Reply
LucienW
LucienW Jul. 31 at 10:09 AM
$PSNL TBH I am not super worried about competition, at least not for now - it’s a big and lucrative market, we can’t expect $PSNL to be the only player in town. I mean, no matter what you do, as long as you are in business, any business, there will always be competition and the most important thing is how you cope. Think about online videos - huge capex, fast content amortization and cut throat competition - it’s probably one of the worst industries to be in. How did $NFLX do? Right? I’d say as a frontrunner in the space, $PSNL has a great setup compared to its competitors. And right now, that’s good enough for me.
1 · Reply
Farorm
Farorm Jul. 31 at 9:12 AM
$PSNL our friend ChatGPT comparing Saga vs Personalis. Expecting reimbursement decision in August.
2 · Reply
Latest News on PSNL
Personalis to Announce Second Quarter 2025 Financial Results

Jul 22, 2025, 4:01 PM EDT - 13 days ago

Personalis to Announce Second Quarter 2025 Financial Results


Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript

May 6, 2025, 8:41 PM EDT - 3 months ago

Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript


Personalis Reports First Quarter 2025 Financial Results

May 6, 2025, 4:01 PM EDT - 3 months ago

Personalis Reports First Quarter 2025 Financial Results


Personalis to Announce First Quarter 2025 Financial Results

Apr 22, 2025, 4:01 PM EDT - 3 months ago

Personalis to Announce First Quarter 2025 Financial Results


Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:40 PM EST - 5 months ago

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript


3 Biotech/Healthcare Names Under $10 I Am Buying Now

Feb 21, 2025, 4:21 PM EST - 5 months ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

ARDX GERN MRNA TEM


Exciting Technology At Personalis, But Profitability Eludes Them

Feb 14, 2025, 10:50 AM EST - 6 months ago

Exciting Technology At Personalis, But Profitability Eludes Them


Personalis and Tempus Expand Collaboration to Biopharma

Dec 16, 2024, 8:00 AM EST - 8 months ago

Personalis and Tempus Expand Collaboration to Biopharma

TEM


Personalis to Participate at Upcoming Investor Conferences

Nov 20, 2024, 4:01 PM EST - 9 months ago

Personalis to Participate at Upcoming Investor Conferences


Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:11 PM EST - 9 months ago

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript


Personalis Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:01 PM EST - 9 months ago

Personalis Reports Third Quarter 2024 Financial Results


Personalis to Present at the Stifel 2024 Healthcare Conference

Nov 5, 2024, 4:01 PM EST - 9 months ago

Personalis to Present at the Stifel 2024 Healthcare Conference


Personalis to Announce Third Quarter 2024 Financial Results

Oct 23, 2024, 4:01 PM EDT - 10 months ago

Personalis to Announce Third Quarter 2024 Financial Results


Personalis: Resetting My Strategy Following The Q2 Beat

Aug 18, 2024, 7:47 AM EDT - 1 year ago

Personalis: Resetting My Strategy Following The Q2 Beat


Personalis and Tempus Announce Expanded Collaboration

Aug 16, 2024, 8:30 AM EDT - 1 year ago

Personalis and Tempus Announce Expanded Collaboration

TEM


Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 11:09 PM EDT - 1 year ago

Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript


Personalis Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Personalis Reports Second Quarter 2024 Financial Results


Personalis to Announce Second Quarter 2024 Financial Results

Jul 24, 2024, 4:01 PM EDT - 1 year ago

Personalis to Announce Second Quarter 2024 Financial Results


Personalis, Inc. (PSNL) Q1 2024 Earnings Call Transcript

May 8, 2024, 11:53 PM EDT - 1 year ago

Personalis, Inc. (PSNL) Q1 2024 Earnings Call Transcript


Personalis Reports First Quarter 2024 Financial Results

May 8, 2024, 4:01 PM EDT - 1 year ago

Personalis Reports First Quarter 2024 Financial Results


Personalis to Announce First Quarter 2024 Financial Results

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Personalis to Announce First Quarter 2024 Financial Results


Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 9:20 PM EST - 1 year ago

Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript


Bulltrader988
Bulltrader988 Aug. 4 at 6:26 PM
$PSNL tomorrow after market 👃👀
0 · Reply
Bulltrader988
Bulltrader988 Aug. 3 at 7:51 PM
$PSNL 👃👀 https://www.nationalgeographic.com/health/article/cancer-recurrence-tumor-dna-blood-test
0 · Reply
Bulltrader988
Bulltrader988 Aug. 2 at 12:31 PM
$PSNL earnings tuesday after market 👃👀
0 · Reply
Wax_Bean_futures
Wax_Bean_futures Aug. 1 at 3:51 PM
$PSNL About to turn green. Rate Cuts on the horizon. Loading more!
0 · Reply
Farorm
Farorm Aug. 1 at 1:12 PM
$PSNL more red to come, yay
1 · Reply
BeeDecay
BeeDecay Aug. 1 at 11:50 AM
$PSNL Some views and opinions. 1. SAGA was fast to get reimbursement. Faster than we hoped for, and for a test with noninferior capabilities in breast cancer. That's a bummer. 2. Personalis has pushed its NeXT Dx through the Medicare reimbursement path back in early 2024, so they know how to do things. Trust the (slow) process. 3. Recall that SAGA's Pathlight uses few SVs whereas we use 1,800 SNVs. In layman's terms: SAGA uses ultra sensitive larger DNA parts specific for a certain tumor type. We use 1,800 SNVs (so looking into single nucleotides, the smallest building blocks of the DNA) that are believed to cover many tumor types. 4. Due to point 3 Personalis should have far less work expanding towards other tumor types, whereas SAGA needs to define the specific SVs for each new indication they want to target. 5. The SAGA and $PSNL approach are more sensitive than the $NTRA approach which is simpler yet generic. Natera used it to be first mover in the MRD space. With success.
0 · Reply
Farorm
Farorm Jul. 31 at 1:46 PM
$PSNL -20% in a week, yay.
1 · Reply
arribaStocktrading
arribaStocktrading Jul. 31 at 12:31 PM
$PSNL Are we all having conversations with AI? So SAGA is a Swedish firm and they have a US presence in Morrisville, NC. They have about 40 employees and were only expected to generate $7 million in Annual Revenues this year. What I was most curious about is how long it took them to gain Medicare reimbursement approval: "SAGA Diagnostics received Medicare coverage for its Pathlight™ MRD test on July 30, 2025, following a rigorous review by Palmetto GBA’s MolDX program. The approval was based primarily on data from the TRACER study, which was published in Clinical Cancer Research in January 2025. That means it took roughly 6 to 7 months from the time their pivotal clinical data was published to the final coverage determination — a relatively swift timeline in the world of molecular diagnostics. "
1 · Reply
LucienW
LucienW Jul. 31 at 10:09 AM
$PSNL TBH I am not super worried about competition, at least not for now - it’s a big and lucrative market, we can’t expect $PSNL to be the only player in town. I mean, no matter what you do, as long as you are in business, any business, there will always be competition and the most important thing is how you cope. Think about online videos - huge capex, fast content amortization and cut throat competition - it’s probably one of the worst industries to be in. How did $NFLX do? Right? I’d say as a frontrunner in the space, $PSNL has a great setup compared to its competitors. And right now, that’s good enough for me.
1 · Reply
Farorm
Farorm Jul. 31 at 9:12 AM
$PSNL our friend ChatGPT comparing Saga vs Personalis. Expecting reimbursement decision in August.
2 · Reply
Farorm
Farorm Jul. 31 at 6:38 AM
$PSNL in a couple of years maybe now it’s about capturing this new market. They are also bringing new tests to the market and if sold through Tempus they have their AI platform as a value add.
0 · Reply
magnitudeFC
magnitudeFC Jul. 31 at 12:20 AM
$PSNL So Saga got approval from MolDx today. Natera is working on their own test. Guardant is too. How is this not a commodity and a race to the bottom?
0 · Reply
mi67
mi67 Jul. 30 at 6:59 PM
$PSNL Is it game over now that Saga Diagnostics got the moidx with much better data than personalis?
2 · Reply
RockyMontana
RockyMontana Jul. 30 at 5:04 AM
$PSNL new director for reimbursement?
3 · Reply
magnitudeFC
magnitudeFC Jul. 30 at 2:34 AM
$PSNL Prasad getting removed is great for us
0 · Reply
LucienW
LucienW Jul. 29 at 7:58 PM
$PSNL here we are. Let’s see what’s next.
0 · Reply
Bulltrader988
Bulltrader988 Jul. 29 at 6:40 PM
$PSNL 🤝🤝 $TEM $PSNL added on this dip today 👃👀
0 · Reply
Skibum77
Skibum77 Jul. 29 at 6:06 PM
$PSNL if we do not hear constructive verifiable comments about an impending approval for reimbursements on the conference call. You can expect it to even even lower.
3 · Reply
BioTechNoir
BioTechNoir Jul. 29 at 5:05 PM
$PSNL reload
0 · Reply
Tfwg
Tfwg Jul. 29 at 4:01 PM
$PSNL price target
0 · Reply
Farorm
Farorm Jul. 29 at 3:51 PM
0 · Reply
ExNoose
ExNoose Jul. 29 at 3:28 PM
$PSNL H&S target $4.83.
2 · Reply